Prospective Open-Label Pilot Study of Arginine Replacement Therapy in Children Hospitalized With COVID-19 (ART-COVID19)

NCT05855330 Phase 2 RECRUITING

This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.

Details

Lead sponsor	Emory University
Phase	Phase 2
Status	RECRUITING
Enrolment	21
Start date	2024-01-08
Completion	2028-06

Conditions

• COVID-19

Interventions

• Arginine Hydrochloride

Primary outcomes

• Change in mitochondrial function — Baseline and day 5
  Complex-IV activity changes will be measured to estimate mitochondrial function before and after administration for L-arginine

Countries

United States